Nova Submits Phase II A Psilocybin Clinical Trial Application to Health Canada
Microdose Psilocybin Safety and Efficacy Clinical Study in Fragile X Syndrome Vancouver, British Columbia – November 30, 2022 – Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) (“NOVA” or the “Company”), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders is proud to announce that the company has submitted to
Read More »
November 30, 2022
Nova Mentis Enters into Research Contract with KGK Science for Phase II A Clinical Trial
Nova Mentis Enters into Research Contract with KGK Science for Phase II A Clinical Trial Vancouver, British Columbia – November 17, 2022 – Nova Mentis Life Science Corp. (CSE: NOVA) (OTCQB: NMLSF) (FSE: HN3Q) (“NOVA” or the “Company”), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders is pleased to announce that it has entered
Read More »
November 17, 2022
Nova Mentis Psilocybin Microdose Capsule Formulation to be Submitted in Health Canada Phase 2A Clinical Trial Application
Vancouver, British Columbia – September 29, 2022 – Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) (“NOVA” or the “Company”), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders is pleased to announce that the company has produced 1.5 mg psilocybin microdose capsules. These capsules were produced according to defined
Read More »
September 29, 2022
Nova Mentis Completes Production of Psilocybin Microdose Capsules
Company Plans to Submit Clinical Trial Application in Canada Vancouver, British Columbia – September 15, 2022 – Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) (“NOVA” or the “Company”), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders is pleased to announce that it has completed production of psilocybin microdose
Read More »
September 15, 2022
Nova Mentis to Present Promising Psilocybin Microdose Data at 18th NFXF International Fragile X Conference
Nova Mentis to Present PromisingPsilocybin Microdose Dataat 18th NFXF International Fragile X Conference Vancouver, British Columbia – July 11, 2022 – Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) (“NOVA” or the “Company”), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders is pleased to announce it will be discussing the therapeutic
Read More »
July 11, 2022
Nova Mentis to Present at the H.C. Wainwright Mental Health Conference
Vancouver, British Columbia – June 22, 2022 – Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) (“NOVA” or the “Company”), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders is pleased to announce that it will be presenting at the H.C. Wainwright 1st Annual Mental
Read More »
June 22, 2022